Study why some lung cancers don’t respond to EGFR pills
Part of Cancer, Lungs & breathing clinical trials.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years
- You have non-small cell lung cancer (NSCLC) that can’t be fully removed or has spread
- You have at least one tumor spot that can be measured on scans
- Your tumor test shows an EGFR mutation (from tissue or fluid such as pleural fluid or spinal fluid)
- You plan to start third-generation EGFR tablets as your first treatment
- You can share medical records, imaging, and provide samples, and you agree to sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study uses leftover tissue or fluid from your lung cancer to test how it responds to different drugs in the lab. The goal is to understand which treatments might work best for tumors with EGFR mutations, which could help guide future treatment decisions.
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.